Living Cell Technologies trying out new treatment for Type 1 diabetes

AUCKLAND, New Zealand A biotech company in New Zealand will try a new way of treating Type 1 diabetes: injecting patients with pig cells.

Living Cell Technologies announced Wednesday that it started a phase 1 and 2a New Zealand clinical trial of Diabecell, an investigative encapsulated pig islet cell product for insulin-dependent diabetes, following authorization by New Zealand’s Ministry of Health.

“The New Zealand trial extends LCT’s clinical program and complements the clinical and commercialization program in Russia,” LCT CEO Paul Tan said in a statement.

The drug is designed to normalize blood glucose levels in people with Type 1 diabetes, comprising encapsulated insulin-producing cells from pigs that can be administered without the need for immunosuppressive drugs, the company said.

Poll

Poll

SPECIAL REPORTS

Are we in the midst of a beauty revolution? Perhaps. It is no secret that the ever-changing beauty category is all about trends, but one could argue that we are embarking on an especially interesting time in beauty as technology is changing the way consumers shop and new innovations strive to break through the noise.

In this beauty report, Drug Store News takes a deeper dive into some of the leading trends that are reshaping beauty.more ...

IN THIS ISSUE

In this issue, DSN examines PricewaterhouseCoopers' "Top Health Industry Issues for 2015;" takes you on a tour of Murad, shares beauty trends and insights and delves into location-based technology and how it is revolutionizing health, retail.Click here to view the issue.